Page 49 - Sinergi Triple Helix Bangun Ekosistem Kemandirian Obat dan Vaksin dalam Negeri

Judul : BPOM in Process of Approving Sinovac Doses for Children Aged 3
Nama Media : en.tempo.co
Tanggal : 8/31/2022
Halaman/URL : https://en.tempo.co/read/1628701/bpom-in-process-of-approving-
sinovac-doses-for-children-aged-3
Tipe Media : Media Online
Jurnalis : Ricky Mohammad Nugraha

The Food and Drugs Monitoring
Agency (BPOM) is currently
processing the emergency use
authorization (EUA) for the
primary dose of the Covid-19
Sinovac vaccine for children aged
3 and above.

Antaranews reported, that the
BPOM has approved three
coronavirus vaccine brands for
children as primary doses or
boosters. These brands include
Sinovac for those aged 6 and
above; Pfizer for children over
12; and Covovax for the 12-year-
old and above.

Of the three types of vaccines for the primary dose, only Pfizer has been approved for use for
homologous boosters (primary vaccine recipients who also received Pfizer), namely in
children aged 16 to 18 years. Only Pfizer has been approved for use as a booster vaccine for
children globally.

BPOM Head Penny K. Lukito revealed this in a House hearing session at Commission IX of
the Indonesian House of Representatives in Jakarta, Tuesday, August 30.

"There is one new booster approved for children by the United States and the United Arab
Emirates, namely Pfizer for ages 5-17. year," she said.

Domestically-made Covid-19 vaccine candidates are also directed at children. This can be
seen from Penny's statement on the Inavac vaccine produced by the team at Airlangga